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Abstract Ferroptosis is a non-apoptotic form of cell
death that can be triggered by small molecules or condi-
tions that inhibit glutathione biosynthesis or the
glutathione-dependent antioxidant enzyme glutathione
peroxidase 4 (GPX4). This lethal process is defined by the
iron-dependent accumulation of lipid reactive oxygen
species and depletion of plasma membrane polyunsaturated
fatty acids. Cancer cells with high level RAS-RAF-MEK
pathway activity or p53 expression may be sensitized to
this process. Conversely, a number of small molecule
inhibitors of ferroptosis have been identified, including
ferrostatin-1 and liproxstatin-1, which can block patho-
logical cell death events in brain, kidney and other tissues.
Recent work has identified a number of genes required for
ferroptosis, including those involved in lipid and amino
acid metabolism. Outstanding questions include the rela-
tionship between ferroptosis and other forms of cell death,
and whether activation or inhibition of ferroptosis can be
exploited to achieve desirable therapeutic ends.
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Introduction
Regulated cell death (RCD) is essential for normal devel-
opment and the maintenance of homeostasis. RCD can
proceed through apoptosis or one of several non-apoptotic
cell death pathways, including the recently described pro-
cess of ferroptosis [1–5]. Ferroptosis is an oxidative, iron-
dependent form of cell death that is distinct from apoptosis,
classic necrosis, autophagy and other forms of cell death
[5] (Table 1). Ferroptosis is triggered by inactivation of
cellular glutathione (GSH)-dependent antioxidant defenses,
leading to the accumulation of toxic lipid ROS (L-ROS) [5,
6] (Fig. 1). This process has recently been implicated in the
pathological cell death of brain tissues exposed to high
levels of glutamate (Glu) as well as kidney and heart tis-
sues subjected to ischemia–reperfusion injury [5, 7–10]. In
the context of cancer, ferroptosis may act as an endogenous
tumor suppressive mechanism downstream of p53 [11]. It
may also be possible to use small molecule activators of
ferroptosis to selectively eliminate cancer cells with
mutations in the RAS-RAF-MEK pathway, although this
remains controversial [6, 12, 13]. It is, therefore, of great
interest to understand how this novel RCD pathway is
regulated.
The recognition of ferroptosis as a unique form
of RCD
The RAS family of small GTPases (HRAS, NRAS and
KRAS) is commonly mutated in cancer and several groups
have searched for small molecules that are selectively
lethal to cells expressing oncogenic mutant RAS proteins
[12, 14–16]. In the 2000’s, the Stockwell laboratory iso-
lated two novel oncogenic RAS Selective Lethal (RSL)
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small molecules named eradicator of Ras and ST (erastin)
and Ras Selective Lethal 3 (RSL3) (Fig. 2a, b) [12, 17].
Both compounds were lethal at lower doses in engineered
human tumor cells expressing oncogenic HRASV12 than in
isogenic cells expressing wild-type HRAS [12, 17]. The
recognition of ferroptosis as a unique form of RCD
emerged, unexpectedly, from characterizing the lethal
mechanism of action of erastin and RSL3.
Erastin and RSL3 treatment do not trigger morpho-
logical changes or biochemical processes consistent with
apoptosis, such as chromatin margination or cleavage of
poly ADP-ribose polymerase (PARP) [12, 13, 17].
Moreover, erastin- and RSL3-induced cell death is not
attenuated by caspase inhibition, by deletion of the
intrinsic apoptotic effectors BCL-2 associated X protein
(BAX) and BCL-2 antagonist/killer 1 (BAK), by a small
molecule inhibitor of necroptosis (e.g. necrostatin-1) or
by inhibition of autophagy (e.g. using chloroquine,
3-methyladenine) [5, 6, 12, 17, 18]. Neither mitochon-
drial ROS production nor the influx of Ca2? is essential
for ferroptosis [5]. However, erastin treatment results in a
unique ‘dysmorphic’ mitochondrial phenotype observ-
able by transmission electron microscopy [5]. Erastin-
induced cell death also depends on a unique set of genes
compared to cell death or cytostasis triggered by pro-
apoptotic or pro-necrotic agents [5]. Crucially, erastin-
and RSL3-induced cell death is effectively inhibited by
the iron chelators DFO, 311, ciclopirox (CPX) and 2,2-
bipyridyl (2,2-BP), as well as by the lipophilic antioxi-
dants trolox (a soluble vitamin E analog), butylated
hydroxyanisole, butylated hydroxytoluene and the novel
synthetic antioxidant ferrostatin-1 (Fer-1) [5, 13,
17] (Fig. 1). These results indicate that iron-dependent
L-ROS accumulation is essential for erastin- and RSL3-
induced cell death. On this basis, the unique erastin- and
RSL3-induced cell death phenotype was named ‘ferrop-
tosis’ [5] (Table 1).
Early studies informing our understanding
of the ferroptotic mechanism
The role of oxidative stress in cell death has been
studied for some time. Pioneering studies in the 1950’s
by Harry Eagle and colleagues examined the amino
acids, vitamins and other nutrients required to support
the growth and proliferation of mammalian cells in
culture [19]. Among those determined to be essential
was cystine (Cys2), the oxidized form of the thiol-con-
taining amino acid cysteine (Cys) [19]. Cells deprived
of Cys2 fail to grow unless cultured at extremely high
densities [19–21]. Following up on these observations,
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cultured human lung fibroblasts of Cys2 resulted in rapid
depletion of the Cys-containing antioxidant tripeptide
GSH (c-L-glutamyl-L-cysteinylglycine), and subsequent
cell death [22]. Cell death was prevented, without res-
cuing GSH levels, by growing cells in the presence of
the lipophilic antioxidant a-tocopherol (vitamin E) [22].
These results implied that Cys2 import was needed to
sustain GSH levels, and that cell death was triggered by
a buildup of L-ROS. In subsequent years, studies of Cys2
deprivation-induced cell death in human embryonic
fibroblasts, neuronal hybridoma cells and rat oligoden-
drocytes confirmed the importance of GSH depletion in
cell death, and demonstrated that both lipophilic
antioxidants and iron chelators could block this process
from occurring [23–26]. Collectively, these reports
established that continuous Cys2 uptake and GSH syn-
thesis are required in many types of mammalian cells to
prevent the accumulation of toxic L-ROS and help frame
our understanding of how erastin and RSL3 trigger fer-
roptosis at the molecular level.
Inhibition of system xc triggers ferroptosis
Analysis of the erastin mechanism of action provided the
first insights into proteins and pathways necessary to pre-
vent the onset of ferroptosis. Early chemoproteomic studies
using erastin analogs conjugated to a solid support matrix
identified the mitochondrial voltage dependent anion
channel 2 and 3 (VDAC2 and VDAC3) as direct erastin
targets [13]. Experiments using purified human VDAC2
reconstituted into artificial liposomes confirm that erastin
can bind this target and modulate transport flux [27].
However, it now appears that the ability of erastin to
trigger ferroptosis is determined mainly by inhibition of a
different target, the cystine/glutamate antiporter termed
system xc [5, 28] (Fig. 1).
System xc is a heterodimeric cell surface amino acid
antiporter composed of the twelve-pass transmembrane
transporter protein SLC7A11 (xCT) linked by a disulfide
bridge to the single-pass transmembrane regulatory protein

















































Fig. 1 Overview of the ferroptosis pathway. In many cells, cystine
(Cys2) import via system x

c is required for glutathione synthesis, and
the function of glutathione peroxidase 4 (GPX4). GPX4 activity
prevents the accumulation of lipid ROS that are lethal to the cell.
Treatment blocks cystine uptake, ultimately depleting the cell of
glutathione and inhibiting the function of GPX4. Direct inhibition of
the rate-limiting glutathione synthetic enzyme glutamate-cysteine
ligase (GCL) using buthionine-(S,R)-sulfoximine (BSO) can also lead
to the same iron- and ROS-dependent ferroptotic phenotype. Other
small molecule inducers of ferroptosis are indicated in red, while
suppressors of ferroptosis are in blue. GCL Glutamate cysteine ligase,
GSS glutathione synthetase, Cys cysteine, Glu glutamate, Gly glycine,
Gln glutamine. a-KG alpha-ketoglutarate, GPNA L-g-glutamyl-p-
nitroanilide, AOA amino oxyacetate, BHA butylated hydroxyanisole,
BHT butylated hydroxytoluene, DFO deferoxamine, 2,2-BP 2,2-
bipyridyl, CPX ciclopirox
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extracellular Cys2 in exchange for intracellular Glu. Using
‘modulatory profiling’ (see [18]) it was found that cell
death induced by erastin is similar in many respects to cell
death induced by sulfasalazine (SAS) [5], a known system
xc inhibitor [30] (Fig. 2a) (Table 2). Notably, the lethal
effects of both SAS and erastin are reversed by co-treat-
ment with b-mercaptoethanol (b-ME) [5, 28], which
bypasses the need for system xc , by forming mixed
disulfides with Cys2 that can be imported into the cell by a
different transporter [31]. Most convincingly, erastin and
SAS block the uptake of radiolabelled Cys2 in cultured
cancer cells [5, 28]. Thus, erastin appears to act as a direct
inhibitor of system xc function. This links the erastin
mechanism of action to a process (Cys-dependent GSH
synthesis) that normally opposes the accumulation of
L-ROS. Indeed, erastin treatment leads to significant
depletion of intracellular GSH, as detected using traditional
biochemical methods and more advanced metabolomics
analyses [6, 7, 28]. It is not known precisely how erastin or
SAS inhibit SLC7A11-mediated Cys2 import. It was ini-
tially proposed that erastin bound to a related transport



























































Fig. 2 Structure of small
molecule ferroptosis inducers. a
molecules that inhibit the
function of system xc .
b Molecules that inhibit the
function of glutathione
peroxidase 4 (GPX4). ML162 is
also known as DPI7
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However, more recent data argue against this possibility,
and suggest that erastin most likely inhibits SLC7A11
directly [28]. More potent and drug-like analogs of erastin
have been described and should facilitate future studies of
the targets and effects of erastin in vitro and in vivo [6, 28,
32].
In addition to erastin and SAS, the FDA-approved multi-
kinase inhibitor sorafenib (trade name: Nexavar) can block
system xc function, deplete GSH and trigger ferroptosis in
cancer cell lines derived from liver, kidney, bone, lung and
other tissues [28, 33, 34] (Table 2) (Fig. 2a). Related
kinase inhibitors have no ability to block system xc func-
tion or cause ferroptosis [28, 33], suggesting that the
effects of sorafenib could be due either to modulation of a
very specific kinase (that in turn modulates system xc
activity) or to a direct effect on system xc . This function
may explain the ability of sorafenib to trigger caspase-
independent cell death in certain cell types and enhance
ROS accumulation in sorafenib-treated cancer patients [35,
36]. Indeed, it is intriguing to speculate that the clinical
benefit of sorafenib observed in patients may be due, at
least in part, to the activation of ferroptosis in vivo [28].
However, the effects of this compound are clearly pleio-
tropic: in some cell lines sorafenib triggers apoptosis [37],
and even in cell lines where ferroptosis is observed at low
doses of sorafenib, apoptosis or some other form of cell
death is observed at higher doses [28]. Further study is
required to disentangle the various effects of sorafenib on
the cell and determine whether the effects of this com-
pound in patients are attributable to ferroptosis.
The role of GPX4 in preventing ferroptosis
Elucidation of the RSL3 mechanism of action provided the
next major insight into the regulation of ferroptosis. Of the
four possible RSL3 diastereomers, only one—1S,3R-
RSL3—is capable of inducing ferroptosis [6] (Fig. 2B).
Chemoproteomic studies using the active isomer of RSL3
as an affinity reagent identified the selenoprotein glu-
tathione peroxidase 4 (GPX4, PHGPx) as a candidate
target of this compound [6] (Fig. 1). GPX4 is a GSH-de-
pendent enzyme that reduces lipid hydroperoxides (L-
OOH) to lipid alcohols (L-OH). GPX4, therefore, normally
limits the iron-dependent formation of highly reactive lipid
alkoxy radicals (L-O) from L-OOH [38, 39]. Cells appear
to be continually exposed to the threat of L-ROS-mediated
destruction, as inhibition of GPX4 activity leads to the
rapid accumulation of L-ROS and cell death in cell culture,
and deletion of Gpx4 in mice is embryonic lethal [6, 39].
Consistent with RSL3-mediated inactivation of GPX4
being essential to induce ferroptosis, overexpression of
GPX4 blocks RSL3-induced cell death while short hairpin
RNA (shRNA)-mediated knockdown of GPX4 in human
oncogenic HRAS cells is sufficient to induce ferroptotic
cell death [6]. Deletion of Gpx4 in mouse cells also results
Table 2 Examples of small molecule-induced ferroptosis
Small molecule Cell line Target Observation References
Erastin, sulfasalazine Engineered human tumor cells,
HT-1080, Calu-1, A-673,
Panc-1, other cancer cell
lines, isolated mouse renal
tubules
System xc Death suppressed by iron chelators
(DFO, CPX), lipophilic
antioxidants (e.g. Fer-1, trolox,






Dixon et al. [5], Linkermann
et al. [8], Dolma et al. [12],
Yagoda et al. [13], Eling
et al. [15], Yang and
Stockwell [17]
Sorafenib HT-1080, Huh7, ACHN System xc Death suppressed by DFO, Fer-1 Dixon et al. [28], Lachaier et al.






Engineered human tumor cells,
HT-1080, Calu-1, others
GPX4 Death suppressed by iron chelators




Yang et al. [6], Dixon et al. [5],
Yang and Stockwell [17],





Death suppressed by lipophilic
antioxidant (Fer-1) and iron
chelation (DFO)
Eling et al. [15]
Buthionine-(S,R)-
sulfoximine
MEFs, HT-1080 GCLC Death suppressed by lipophilic
antioxidant (a-tocopherol, Fer-1)
and iron chelation (DFO)
Friedmann Angeli et al. [9],
Seiler et al. [39]
MEFs mouse embryonic fibroblasts, BSO buthionine-(S,R)-sulfoximine, GCLC glutamate-cysteine ligase, catalytic subunit, DFO deferoxamine
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in cell death that can be suppressed by lipophilic antioxi-
dants (e.g. Fer-1) and iron chelators, further confirming that
GPX4 activity is essential to prevent ferroptosis [9, 39].
In addition to RSL3, nine other synthetic small mole-
cules, including ML162 (also known as DPI7), ML210
(also known as DPI10) and, most unexpectedly, the FDA-
approved anticancer agent altretamine, can inhibit GPX4
activity [6, 16, 40] (Table 2; Fig. 2b). Like RSL3, these
compounds inhibit GPX4 enzymatic activity without
depleting the cell of glutathione. Thus, RSL3 and func-
tionally related compounds are classified as ‘‘class 2’’
ferroptosis-inducing compounds (FINs), to distinguish
them from erastin and other system xc inhibitors that that
most likely block GPX4 function indirectly by preventing
GSH synthesis (‘‘class 1’’ FINs) [6, 40]. Mechanistically,
how RSL3 and other class 2 FINs bind GPX4 to inhibit its
activity is not known.
Ferroptosis can be induced by glutathione
depletion
Ferroptosis can be induced by depriving cells of the
essential GSH precursor, Cys, or by blocking the function
of the GSH-dependent enzyme GPX4 (see above). Thus,
direct inhibition of GSH synthesis would be predicted to
trigger ferroptosis. Consistent with this prediction, inhi-
bition of glutamate-cysteine ligase (GCL, formerly known
as c-glutamylcysteine synthetase), the rate-limiting first
enzyme in the two-step synthesis of GSH, using
buthionine-(S,R)-sulfoximine (BSO [41]), can induce cell
death that is suppressed by a-tocopherol and DFO, but
not by the caspase inhibitor zVAD-fmk or the necroptosis
inhibitor Nec-1 [9, 39]. This suggests that inhibition of
GSH synthesis is sufficient to trigger ferroptosis, at least
in some cells (Fig. 1). Curiously, however, in many fer-
roptosis-sensitive cells BSO is a far less potent inducer of
ferroptosis than inhibition of system xc or GPX4 (J. Cao
& S. Dixon, unpublished). One possibility is that direct
GCL inhibition leads to upregulation of an alternative
antioxidant pathway that can maintain cell survival in the
absence of GSH. For example, high levels of SLC7A11-
mediated Cys2 import, in conjunction with the GSH-in-
dependent thioredoxin (Txn) system, can substitute for the
essential function of the GSH-GPX4 lipid peroxide
metabolic pathway in some cells both in vitro and in vivo
[42–44]. Mechanistically, this might involve the transfer
of reducing equivalents from Cys2 to Txn (via thioredoxin
reductase) in sufficient quantities to maintain the
endogenous lipid antioxidant a-tocopherol in a reduced
state, and thereby, prevent L-ROS accumulation [45].
Regarding the connection between GSH and cell death, a
major issue remaining to be resolved concerns the type of
cell death induced by GSH depletion. As described above,
in some cells GSH depletion can trigger ferroptosis.
However, GSH depletion has also been associated with
the induction of apoptosis and sensitization to apoptosis-
inducing agents (e.g., SMAC mimetics) [46–48]. While
more work is required to reconcile the latest findings
concerning the role of GSH in ferroptosis with the liter-
ature linking GSH depletion and apoptosis, a speculative
model is that the depletion of cytosolic GSH promotes
ferroptosis, while the depletion of the separate mito-
chondrial GSH pool promotes, or is more closely
associated with, apoptosis [9, 49].
The causes of ferroptotic cell death downstream
of GSH depletion and GPX4 inactivation
In response to system xc inhibition or GPX4 inactivation,
ferroptotic cell death involves the iron-dependent accu-
mulation of L-ROS and the depletion of polyunsaturated
fatty acids (PUFAs) [5–7, 9]. L-ROS are typically formed
from the PUFA chains of membrane lipids. PUFAs are
susceptible to both enzymatic (e.g., lipoxygenase-cat-
alyzed) and non-enzymatic (e.g., ROS-catalyzed)
oxidation, leading to the formation of lipid hydroperoxides
(L-OOH) [50]. In the presence of iron, L-OOH can form
toxic lipid radicals such as the alkoxy radical L-O. These
lipid radicals can abstract protons from adjacent PUFAs,
initiating a new round of lipid oxidation and further
propagation of oxidative damage from one lipid to another
[50]. PUFA oxidation and free-radical-mediated damage
can ultimately result in PUFA fragmentation into a variety
of products [50]. In erastin-treated cancer cells and Gpx4
null mouse cells, L-ROS accumulation, PUFA depletion
and cell death are all prevented by treatment with small
molecule antioxidants such as Fer-1, suggesting that lipid
ROS-mediated damage is essential for ferroptosis [5, 7, 9].
The recently described ferroptosis inhibitor, liproxstatin-1,
may also function as a lipophilic antioxidant, although the
mechanism of action of this inhibitor has yet to be reported
[9].
In cells undergoing ferroptosis the PUFA arachidonic
acid (AA) is significantly depleted and AA-derived lipid
fragments are detected in the supernatants of Gpx4-/-
mouse embryonic fibroblasts (MEFs) [7, 9]. Consistent
with a key role for AA in ferroptosis, the deletion of two
genes, acyl-CoA synthetase long-chain family member 4
(ACSL4) and lysophosphatidylcholine acyltransferase 3
(LPCAT3), prevents ferroptosis induced by the GPX4
inhibitors RSL3 and ML162 [51]. ACSL4 and LPCAT3
encode enzymes involved in the insertion of AA into
membrane phospholipids [52, 53]. This suggests that the
execution of ferroptosis can only proceed, following direct
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or indirect (i.e., GSH depletion-induced) inactivation of
GPX4, when highly oxidizable PUFAs such as AA are
present in the membrane.
The molecular events that occur downstream of PUFA
oxidative fragmentation to cause irreversible cell death are
unclear. PUFA fragmentation and membrane lipid damage
may be sufficient to irreversibly permeabilize the plasma
membrane. Alternatively or in parallel, reactive lipid
intermediates generated following PUFA oxidation could
promote cell death by covalently modifying and inacti-
vating essential intracellular proteins. In support of this
possibility, cell lines selected for resistance to ferroptosis
overexpress three aldo–keto reductase family 1, member C
(AKR1C) family members [28]. These proteins can
detoxify the toxic reactive lipid intermediate 4-hydrox-
ynonenal (4-HNE), which can be formed downstream of
oxidative PUFA fragmentation [54, 55]. A plausible model
is that the activity of AKR1C family members can restrain
ferroptosis by preventing the accumulation of 4-HNE to
toxic levels, but functional studies are required to investi-
gate this hypothesis in detail.
The role of iron in ferroptosis
Iron is essential for the execution of ferroptosis. Both
membrane permeable (e.g. CPX, 311 and 2,2-BP) and
membrane impermeable (e.g. DFO) iron chelators prevent
cells from undergoing ferroptosis, whether induced by
erastin, RSL3 or a physiological stimulus such as high
concentrations of extracellular Glu [5, 6, 17]. Likewise,
ferroptosis induced by erastin or Cys2 deprivation is pre-
vented by genetic silencing of TFRC, which encodes the
transferrin receptor required for the uptake of transferrin-
iron complexes into the cell [10, 17]. Conversely, supple-
menting the growth medium with iron-bound transferrin or
a bioavailable form of iron (e.g., ferric ammonium citrate),
but not other divalent metals, accelerates erastin-induced
ferroptosis [5, 10]. These results firmly establish the need
for iron in ferroptosis.
How iron promotes ferroptosis inside the cell remains
unclear. Although a redox-independent role for iron cannot
formally be ruled out, the most obvious explanation for the
ability of iron chelators to block ferroptosis is that they
prevent iron from donating electrons to oxygen to form
ROS [56]. The properties of different iron chelator classes
provide some insights. Lipophilic iron chelators can cross
the plasma membrane and chelate the intracellular free,
‘redox active’ iron pool [57]. This may block death by
preventing this iron pool from catalyzing the formation of
soluble or lipid radicals that can initiate or propagate
oxidative PUFA fragmentation, respectively [50]. Alter-
natively or in parallel, lipophilic iron chelators may
directly inactivate iron-containing enzymes that promote
membrane lipid oxidation. In this connection, the lipoxy-
genase (LOX) family of enzymes are interesting candidates
to mediate iron-dependent L-ROS formation. The iron-
dependent LOX enzymes catalyze site-specific oxidation of
PUFAs such as AA, and are directly inactivated by lipo-
philic iron chelators [58–60]. Small molecule LOX
inhibitors block cell death due to depletion of GSH or
deletion of Gpx4 [39, 61, 62]; however, protection from
Gpx4 deletion is not observed when different Lox enzymes
are inactivated using genetic reagents individually or in
combination [9, 39]. Other iron-dependent enzymes,
including the iron and 2-oxoglutarate-dependent dioxyge-
nase prolyl 4-hydroxylase isoform 1 (PHD1) may also be a
relevant target of iron chelator action in the prevention of
GSH depletion-induced cell death [63]. However, a
molecular mechanism linking PHD1 function to the pro-
duction of L-ROS is less obvious than for LOX enzymes
which are known to oxidize PUFAs directly.
Unlike lipophilic iron chelators, DFO is a membrane
impermeable iron chelator that accumulates in the lyso-
some through endocytosis [59]. This suggests that DFO
likely prevents ferroptosis by chelating lysosomal iron.
However, unlike lethal treatments such as H2O2, that cause
the destruction of the lysosome [64], there is no evidence
that ferroptosis-inducing compounds such as erastin trigger
lysosomal bursting [7]. Thus, a reasonable model is that
DFO, acting within the lysosome, intercepts iron that is
ultimately destined for another location in the cell more
directly responsible for promoting L-ROS formation (e.g.,
the ‘redox active’ pool and/or a specific iron-dependent
enzyme).
Iron chelation not only prevents ferroptosis, but also cell
death induced by H2O2 and the synthetic compound arte-
sunate [5]. However, cell death in response to these lethal
triggers is typically not blocked by ferroptosis-specific
antioxidants such as Fer-1 [5], suggesting that in most cells
these agents do not induce ferroptosis per se (but see [65]).
Therefore, the combined use of both iron chelators and
lipophilic antioxidants is required to definitively assess the
role of ferroptosis in a particular lethal phenotype.
Modulators of ferroptosis
Hypothesis-driven investigations and unbiased loss-of-
function genetic screens have identified genes that are
essential for, or that modulate the sensitivity to, ferroptosis
(Table 3). Ferroptosis was originally characterized through
the study of compounds (i.e., erastin, RSL3) that are
selectively more lethal to oncogenic RAS mutant cancer
cells. Additional RSL compounds have been identified on
the basis of this cellular phenotype, and subsequently
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confirmed to trigger ferroptosis (e.g. [6, 16]). These results
suggest a relationship between ferroptosis and oncogenic
RAS activity, at least in certain cells. In KRAS-mutant
Calu-1 lung cancer cells shRNA-mediated silencing of
KRAS reduces sensitivity to erastin [13]. Silencing of
oncogenic mutant BRAF in A-673 cells also reduces sen-
sitivity to erastin [13], suggesting that the activity of the
broader RAS-RAF-MEK pathway could determine fer-
roptosis sensitivity in individual cell lines. Constitutive
RAS pathway activity can promote the expression of TFRC
and suppress the expression of iron storage proteins in
engineered tumor cell lines, providing one explanation for
how oncogenic RAS activity could promote sensitivity to
ferroptosis [17]. However, this model remains to be tested
in additional cell types.
The link between RAS pathway activity and ferroptosis
is complicated by two observations. First, when comparing
profiles of erastin sensitivity across a panel of 117 cancer
cell lines, RAS-mutant cancer cell lines are on average no
more sensitive to ferroptosis-inducing compounds than
cancer cells expressing wild-type RAS [6]. In fact, for
unknown reasons, diffuse large B cell lymphoma (DLBCL)
and renal cell carcinoma cancer cell lines, which do not
typically contain RAS pathway mutations, emerge as the
most sensitive types of cancer cells [6]. Second, RMS13
rhabdomyosarcoma cells overexpressing oncogenic HRAS,
Table 3 Genes and proteins identified as mediators or modulators of ferroptosis
Gene Identification
method
Gene product Gene product function References
TFRC Candidate gene,
RNAi
Transferrin receptor Import of transferrin-iron complexes Yang and Stockwell
[17], Gao et al.
[10]
ACSF2 shRNA screen Acyl-CoA synthetase family member 2 Fatty acid metabolism Dixon et al. [5]
EMC2/
TTC35
shRNA screen ER membrane protein complex subunit 2 Unknown. Possible role in protein
folding in the endoplasmic reticulum
Dixon et al. [5]
RPL8 shRNA screen Ribosomal protein L8 Core component of the ribosomal large
subunit involved in protein synthesis.
Dixon et al. [5]
IREB2 shRNA screen Iron-responsive element binding protein 2 Master regulator of iron homeostasis Dixon et al. [5]
SLC7A11 Candidate gene
approach
Solute carrier family 7 (anionic amino acid
transporter light chain, xc- system), member
11
Cystine/glutamate antiporter. Dixon et al. [5]
CS shRNA screen Citrate synthase Lipid metabolism Dixon et al. [5]
ATP5G3 shRNA screen ATP synthase, H ? transporting, mitochondrial
Fo complex, subunit C3 (subunit 9)
Complex V of mitochondrial FoF1
ATPase; ATP synthesis
Dixon et al. [5]
GPX4 Candidate gene
approach
Glutathione peroxidase 4 Lipid repair Yang et al. [6]
GCLC Candidate gene
approach




Acyl-CoA synthetase long-chain family
member 4










Cysteinyl-tRNA synthetase Protein translation Hayano et al. [67]
SLC1A5 Candidate gene
approach
Solute carrier family 1 (neutral amino acid
transporter), member 5
Glutamine transport Gao et al. [10]
GLS2 Candidate gene
approach
Glutaminase 2 (liver, mitochondrial) Glutaminolysis Gao et al. [10]
GOT1 Candidate gene
approach
Glutamic-oxaloacetic transaminase 1, soluble Glutaminolysis Gao et al. [10]
HSPB1 Candidate gene
approach
Heat shock 27 kDa protein 1 Protein folding; iron metabolism Sun et al. [87]
TP53 Candidate gene
approach
Tumor protein p53 Tumor suppressor, metabolic regulator Jiang et al. [11]
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KRAS or NRAS are resistant to erastin and RSL3 [66]. A
reasonable explanation for this confusing picture is that the
effects of RAF-MEK-ERK pathway activity on ferroptosis
differ depending on cell lineage or mutant RAS protein
expression levels. The discovery of biomarkers that more
universally predict sensitivity and resistance to ferroptosis
would help guide the development of these agents for
cancer treatment.
In addition to RAS pathway components, additional
genes have been found to modulate ferroptosis (see
Table 3). These genes can be linked to processes known to
be essential for ferroptosis, including iron metabolism
(TFRC, IREB2, HSPB1), protein synthesis (RPL8) and
lipid metabolism (ACSF2, ACSL4, LPCAT3, and possibly
CS). Silencing of CARS, and certain other tRNA syn-
thetases (HARS, EPRS), appears to promote cell survival
indirectly, by enhancing the synthesis of Cys from
methionine, via the transsulfuration pathway, allowing the
cell to maintain GSH synthesis when system xc is blocked
by erastin [67]. SLC1A5, GLS2 and GOT1 are required for
glutamine uptake and metabolism to Glu and, ultimately,
a-ketoglutarate [10]. The role of Gln metabolism in fer-
roptosis is not clear, although this pathway may contribute
to the formation of oxidizable membrane lipids by feeding
precursors (i.e., citrate) towards fatty acid or lipid synthesis
[5]. The role of other genes (ATP5G3, EMC2/TTC35) in
ferroptosis has yet to be studied in detail.
Another recently described modulator of ferroptosis is
p53, encoded by TP53. Using a p53-inducible cell line, p53
upregulation was shown to repress expression of the system
xc transporter subunit SLC7A11 and sensitize cells to
ferroptosis [11]. Chromatin immunoprecipitation and elec-
trophoretic mobility shift analysis experiments suggest that
p53 binds to the SLC7A11 locus at a specific p53 response
element within the 5’ untranslated region. At this site, p53
presumably recruits chromatin-modifying enzymes that
repress SLC7A11 transcription. These results are of great
interest since the mechanism of p53-mediated tumor sup-
pression remains highly controversial. While early literature
suggested that p53-dependent tumor suppression involved
the induction of cell cycle arrest, senescence or apoptosis,
the recent analysis of several transactivation-defective p53
mutants has called this model into question and it now
appears that alterations in intracellular metabolism may
account for the ability of p53 to suppress tumor formation
[68–70]. p53-dependent effects on SLC7A11-mediated Cys2
uptake fit within this emerging picture of p53-dependent
metabolic modulation, although it should be noted that
SLC7A11 was not identified in other comprehensive studies
of genomic p53 binding sites and direct p53 transcriptional
targets [71, 72]. Moreover, p53 is known to induce the
expression of a number of antioxidant genes that would be
predicted to suppress ROS accumulation, and therefore
counteract ferroptosis [70]. Resolving the role of p53 in
ferroptosis promises to be an active area of investigation.
The role of ferroptosis in pathological cell death
A role for ferroptosis has been found in a growing number
of pathological cell death scenarios (Table 4). These
studies have been enabled by the discovery of novel small
Table 4 Known and suspected physiological or pathological ferroptosis-inducing conditions
Treatment System Observation References
Glutamate Rat postnatal hippocampal
slice culture
Death suppressed by Fer-1,
CPX
Dixon et al. [5]
Cystine deprivation Rat postnatal pre-
oligodendrocyte cultures




corticostrial rat brain slice
Death suppressed by Fer-1 Skouta et al. [7]
Iron overload Mouse kidney proximal
tubules
Death suppressed by Fer-1 Skouta et al. [7]
Acetaminophen Mouse hepatocytes Death suppressed by Fer-1 L}orincz et al. [88]
Gpx4 deletion MEFs, mouse kidney cells,
mouse T cells
Rapid death, suppressed by
vitamin E, Fer-1
Friedmann Angeli et al. [9], Matsushita
et al. [89], Seiler et al. [39]
p53 upregulation MEFs p53 upregulation leads to
sensitization to ferroptosis
Jiang et al. [11]
Ischemia/reperfusion Mouse kidney (in vivo),
mouse heart (ex vivo)
Death suppressed by Fer-1
analogs, iron chelation
Gao et al. [10], Linkermann et al. [8]
Amino acid deprivation in
presence of serum and glucose
MEFs Death suppressed by Fer-1 Gao et al. [10]
MEFs mouse embryonic fibroblasts, b-ME beta-mercaptoethanol
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molecules, including Fer-1 [5], improved Fer-1 analogs [7,
8] and liproxstatin-1 [9], that potently and specifically
block ferroptosis. In a rat hippocampal slice culture model,
exposure to high concentrations of Glu triggers substantial
cell death that can be significantly attenuated by both Fer-1
and the iron chelator CPX [5]. Complete protection from
cell death is observed with Fer-1 and several Fer-1 analogs
in rat oligodendrocytes deprived of Cys2, a model of the
pathological process leading to periventricular leukomala-
cia, while more modest protection is observed in a model
of Huntington’s disease and in a model of iron-induced
kidney tubule damage [7]. Fer-1 and improved analogs also
protect isolated renal tubules from erastin-induced cell
death, reduce kidney injury following acute oxalate-in-
duced damage, and protect from acute renal failure and
organ damage in a model of severe kidney ischemia/
reperfusion injury [8]. In a similar vein, the novel ferrop-
tosis inhibitor liproxstatin-1 attenuates cell death in, and
extends survival of, mice in which Gpx4 is selectively
deleted from the kidney [9]. Finally, both DFO and the
glutaminolysis inhibitor Compound 968 prevent cell death
in an ex vivo model of ischemia/reperfusion injury in the
mouse heart [10]. While these results are suggestive of
ferroptosis in this pathological scenario, further work using
ferroptosis-specific inhibitors such as Fer-1 will be helpful
to confirm this point.
These studies suggest a number of tissues and sce-
narios where the induction of ferroptosis may contribute
to pathological cell death. One concern with the ex vivo
model studies is that ambient levels of oxygen (O2, i.e.,
21 %) artificially enhances any oxidative cell death
process under consideration. While this cannot be com-
pletely ruled out, studies of mouse and human cells show
that both erastin treatment and Gpx4 inactivation trigger
ferroptosis with similar inhibition profiles and cell death
phenotypes at both ambient (i.e., 21 %) and physiolog-
ical (\5 %) levels of O2, suggesting that ferroptotic
mechanisms remain active in low oxygen conditions [28,
39]. A second concern associated with these studies is
that it is impossible to know, with certainty, that Fer-1
and other inhibitors are blocking ferroptosis and not
another form of cell death. This is because we currently
lack suitable molecular markers of ferroptosis that would
identify cells undergoing this process, prior to death.
While the mRNA expression levels of two genes pros-
taglandin E synthase 2 (PTGES2) and ChaC glutathione-
specific gamma-glutamylcyclotransferase 1 (CHAC1) are
significantly elevated in cells undergoing ferroptosis [6,
28], these are not suitable for use in live cells or intact
tissues. Further work is needed to identify additional
ferroptotic markers that could be used for future in vivo
studies.
Ferroptosis and oxidative glutamate toxicity
Ferroptosis appears similar in several respects to oxidative
glutamate toxicity (OGT), a phenotype observed in certain
neuronal cell lines treated with high concentration of Glu to
inactivate system xc and deprive the cell of Cys2 (e.g. [25,
73–75]). Both erastin-induced ferroptosis and OGT involve
GSH depletion, L-ROS accumulation and cell death that
can be blocked by lipophilic antioxidants including Fer-1
[5, 25, 62, 73, 76, 77]. However, as discussed previously
(see [5, 56]), a number of key differences between fer-
roptosis and OGT are apparent, downstream of L-ROS
accumulation. For example, in OGT, but not ferroptosis,
extracellular Ca2? influx, BH3 interacting domain death
agonist (Bid)-mediated mitochondrial damage and nuclear
translocation of apoptosis inducing factor 1 (AIF1) are
essential for death [62, 73, 78]. Thus, while ferroptosis and
OGT can share a common mechanism of initiation (i.e.
Cys2 deprivation), the terminal phases of death execution
appear to be more complex and elaborate in cells under-
going OGT. Of note, AIF1 is reportedly essential for cell
death in MEFs lacking Gpx4 [39], although this result
remains to be confirmed in other cells. Whether ferroptosis
is an abbreviated form of OGT specific to cancer cells, or
whether OGT is a more elaborate form of ferroptosis
specific to neuronal cells, remains to be resolved.
Conclusions and perspectives
Ferroptosis lies at the nexus of essential biological pro-
cesses involving O2, iron and PUFAs. O2, iron and PUFAs
are, individually, essential for cell growth and proliferation.
However, the interaction between O2, iron and PUFAs can
lead to the accumulation of toxic levels of L-ROS. Thus,
ferroptosis results from an imbalance between O2-depen-
dent, iron-catalyzed, L-ROS production and GSH-
Fe2+ O2 Ferroptosis
Cell growth and proliferation
PUFA
GSH
Fig. 3 The relationship between iron, diatomic oxygen (O2), PUFAs
and glutathione (GSH). Iron (Fe2?), O2 and PUFAs are each,
individually, required for cell growth and survival (green arrows).
GSH is also required for cell growth and proliferation, as well as to
prevent the combination of Fe2?, O2 and PUFAs from triggering
ferroptosis
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dependent GPX4 activity (Fig. 3). Compared to other
forms of RCD, the ‘logic’ of the ferroptosis pathway is
unique. Apoptosis, for example, is triggered by diverse
lethal stimuli (e.g. DNA damage, protein misfolding, etc.)
leading to activation of a latent, pro-death enzymatic pro-
gram and the ordered disassembly of the cell. Ferroptosis,
by contrast, results from the inactivation of an essential
metabolic process, leading to an iron-catalyzed, L-ROS-
mediated cellular collapse. It has been noted by Green and
Victor that ferroptosis is therefore best described as a form
of cellular ‘sabotage’, wherein the normal metabolic
functions of the cell contribute to cell death [79]. This
distinguishes ferroptosis from apoptosis and other forms of
RCD that are best described as ‘cell suicide’ [79]. Whether
the inactivation of any other essential metabolic processes
can trigger ferroptosis, or perhaps other novel cell sabotage
programs, is unknown.
The distinction between ferroptosis as a form of cell
sabotage and apoptosis as a form of cell suicide is
intriguing, but begs the question of why cell sabotage
might exist in the first place. Why does GSH depletion and
GPX4 inactivation not simply trigger apoptosis? Is there
something unique about GSH depletion and/or GPX4
inactivation that would make an alternative form of death
like ferroptosis inevitable? One possibility is that GSH is
required for the execution of apoptosis and that GSH
depletion therefore inhibits the apoptotic program. While
certain cancer cells treated with BSO (to deplete GSH) are
unable to activate apoptosis in response to lethal doses of
various alkylating agents, GSH is apparently not required
for apoptotic cell death in response to most lethal triggers
[80, 81]. Thus, it seems that cells depleted of GSH are fully
capable of undergoing apoptosis, and yet still typically
adopt a ferroptotic fate.
An alternative model is that GSH depletion is ‘insulated’
from the apoptotic pathway to enable it to produce a
specific, adaptive cellular phenotype. In cells undergoing
ferroptosis caspases are not activated [13] and dying cells
are therefore likely to release a number of immune mod-
ulators [8]. This may be beneficial if the goal is to trigger
an immune response. Interestingly, the system xc trans-
porter SLC7A11 is required for entry of Kaposi’s sarcoma-
associated herpesvirus into certain cells [82], a process
likely to disrupt normal glutathione homeostasis. Likewise
infection of immune cells with the human immunodefi-
ciency virus type-1 (HIV-1) is well know to cause
dysregulation of glutathione homeostasis [83, 84], possibly
enhancing sensitivity to ferroptosis. Thus, ferroptosis may
be a fate preferentially adopted by certain immune cells, in
response to infection, to ensure the release of appropriate
immunostimulatory signals. More broadly, low levels of
intracellular Cys and GSH may be sensed, like ATP and
acetyl-CoA, as indicators of poor cell health and constitute
a novel ‘metabolic checkpoint’ [85]. Cells with low levels
of antioxidant defenses accumulate DNA damage more
readily [86] and in multicellular organisms it could,
therefore, be adaptive to have a specific route available for
these cells to be eliminated. Future studies of ferroptosis
promise to illuminate these and other questions surround-
ing this intriguing cell death process.
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